Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide versus insulin glargine for beta-cell function in type 2 diabetes on metformin
2004-000577-65Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2004
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Exenatide + metformin with Insulin glargine + metformin (2 arms). Primary endpoint: Beta-cell function by arginine-stimulated insulin secretion during hyperglycemic clamp. Started Jul 2004; status: completed.
02
Drugs
exenatideinsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2004-000577-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000577-65.